
PHARMACEUTICAL 2023



REGENERX BIOPHARMACEUTICALS INC Rank 421 of 446





REGENERX BIOPHARMACEUTICALS INC Rank 421 of 446

The relative strengths and weaknesses of REGENERX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 40% points. The greatest weakness of REGENERX BIOPHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 204% points.

The company's Economic Capital Ratio, given in the ranking table, is -364%, being 407% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	307
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	554
Liabilities, Non-Current	1,901
Other Assets	75
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,373
Other Net Income	-325
Other Revenues	77
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	1,479

Output Variable	Value in 1000 USD
Assets	382
Liabilities	3,828
Expenses	1,479
Revenues	77
Stockholders Equity	-3,445
Net Income	-1,727
Comprehensive Net Income	-1,727
Economic Capital Ratio	-364%

